NDA Submitted for Durasert 3-Year Implant for Posterior Segment Uveitis
The NDA submission was supported by data from two Phase 3 studies that met the primary efficacy endpoint of prevention of recurrence of uveitis at 6 months of follow-up (P<0.001).
